Monopar Therapeutics (MNPR) Short Interest Ratio & Short Volume → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free MNPR Stock Alerts $0.61 -0.01 (-1.61%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Monopar Therapeutics Short Interest DataCurrent Short Volume92,300 sharesPrevious Short Volume150,000 sharesChange Vs. Previous Month-38.47%Dollar Volume Sold Short$60,927.32Short Interest Ratio / Days to Cover0.0Last Record DateApril 30, 2024Outstanding Shares17,480,000 sharesFloat Size7,450,000 sharesShort Percent of Float1.24%Today's Trading Volume39,401 sharesAverage Trading Volume53,139 sharesToday's Volume Vs. Average74% Short Selling Monopar Therapeutics ? Sign up to receive the latest short interest report for Monopar Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMNPR Short Interest Over TimeMNPR Days to Cover Over TimeMNPR Percentage of Float Shorted Over Time Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond Monopar Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202492,300 shares $60,927.32 -38.5%1.2%0 $0.66 4/15/2024150,000 shares $114,000.00 -12.0%2.0%0 $0.76 3/31/2024170,500 shares $116,110.50 -25.7%2.3%0 $0.68 3/15/2024229,600 shares $149,469.60 -73.0%3.6%0 $0.65 2/29/2024848,800 shares $704,504.00 +1,251.6%13.3%0.2 $0.83 2/15/202462,800 shares $21,358.28 +192.1%1.0%0 $0.34 Get the Latest News and Ratings for MNPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202421,500 shares $7,213.25 -76.6%0.3%0.1 $0.34 1/15/202491,900 shares $39,939.74 -12.8%1.4%0.1 $0.43 12/31/2023105,400 shares $35,857.08 +51.4%1.7%0.1 $0.34 12/15/202369,600 shares $25,661.52 -59.0%1.1%0.1 $0.37 11/30/2023169,900 shares $50,970.00 -9.5%2.8%0.2 $0.30 11/15/2023187,800 shares $62,011.56 +277.9%3.1%0.2 $0.33 10/31/202349,700 shares $22,315.30 +7.8%0.9%0.1 $0.45 10/15/202346,100 shares $21,256.71 +27.0%0.8%0.3 $0.46 9/30/202336,300 shares $22,502.37 -43.9%0.6%0.1 $0.62 9/15/202364,700 shares $39,169.38 -33.0%1.1%0.3 $0.61 8/31/202396,600 shares $62,403.60 -65.8%1.9%0.4 $0.65 8/15/2023282,600 shares $192,168.00 +361.0%5.5%0.6 $0.68 7/31/202361,300 shares $45,423.30 +53.3%1.3%0.1 $0.74 7/15/202340,000 shares $40,000.00 -65.4%0.8%0.1 $1.00 6/30/2023115,600 shares $98,838.00 -58.6%2.4%0.4 $0.86 6/15/2023279,100 shares $235,923.23 +231.1%5.7%1 $0.85 5/31/202384,300 shares $82,445.40 +6.6%1.7%0.3 $0.98 5/15/202379,100 shares $68,026.00 +4.9%1.4%2.6 $0.86 4/30/202375,400 shares $84,832.54 +20.8%1.4%2.3 $1.13 4/15/202362,400 shares $78,761.28 -32.5%1.1%1.7 $1.26 3/31/202392,400 shares $128,445.24 +41.1%1.7%2.5 $1.39 3/15/202365,500 shares $172,265.00 +65.0%1.2%2.9 $2.63 2/28/202339,700 shares $124,261.00 +25.6%0.8%1.4 $3.13 2/15/202331,600 shares $116,920.00 -36.2%0.6%1.2 $3.70 1/31/202349,500 shares $177,210.00 +269.4%0.9%1.3 $3.58 1/15/202313,400 shares $36,602.10 +78.7%0.3%0.4 $2.73 12/30/20227,500 shares $17,775.00 -72.7%0.1%0.2 $2.37 12/15/202227,500 shares $72,875.00 -32.4%0.5%0.9 $2.65 11/30/202240,700 shares $104,599.00 +26.8%0.8%1.6 $2.57 11/15/202232,100 shares $90,201.00 +98.2%0.6%1.3 $2.81 10/31/202216,200 shares $39,852.00 +47.3%0.3%0.7 $2.46 10/15/202211,000 shares $19,800.00 -37.5%0.2%1.1 $1.80 9/30/202217,600 shares $26,752.00 +50.4%0.3%1.7 $1.52 9/15/202211,700 shares $19,072.17 +62.5%0.2%1.1 $1.63The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. MNPR Short Interest - Frequently Asked Questions What is Monopar Therapeutics' current short interest? Short interest is the volume of Monopar Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 92,300 shares of MNPR short. 1.24% of Monopar Therapeutics' shares are currently sold short. Learn More on Monopar Therapeutics' current short interest. What is a good short interest percentage for Monopar Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.24% of Monopar Therapeutics' floating shares are currently sold short. Is Monopar Therapeutics' short interest increasing or decreasing? Monopar Therapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 92,300 shares, a decrease of 38.5% from the previous total of 150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Monopar Therapeutics' float size? Monopar Therapeutics currently has issued a total of 17,480,000 shares. Some of Monopar Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Monopar Therapeutics currently has a public float of 7,450,000 shares. How does Monopar Therapeutics' short interest compare to its competitors? 1.24% of Monopar Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Monopar Therapeutics: ABVC BioPharma, Inc. (7.35%), Elevai Labs, Inc. (0.44%), Akari Therapeutics, Plc (0.03%), Avalo Therapeutics, Inc. (10.13%), MIRA Pharmaceuticals, Inc. (0.42%), Moleculin Biotech, Inc. (1.45%), Guardion Health Sciences, Inc. (14.33%), Aeterna Zentaris Inc. (0.34%), Imunon, Inc. (3.95%), Eterna Therapeutics Inc. (1.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Monopar Therapeutics stock? Short selling MNPR is an investing strategy that aims to generate trading profit from Monopar Therapeutics as its price is falling. MNPR shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Monopar Therapeutics? A short squeeze for Monopar Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MNPR, which in turn drives the price of the stock up even further. How often is Monopar Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MNPR, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ABVC Short Squeeze ELAB Short Squeeze AKTX Short Squeeze AVTX Short Squeeze MIRA Short Squeeze MBRX Short Squeeze GHSI Short Squeeze AEZS Short Squeeze IMNN Short Squeeze ERNA Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MNPR) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press